Physiologically based pharmacokinetic (PBPK) modeling of drug-drug interactions between suraxavir marboxil and CYP3A4 inhibitors: Quantitative prediction of pharmacokinetic effects on active metabolite GP1707D07

Suraxavir marboxil (GP681) is a promising novel prodrug influenza polymerase acidic (PA) inhibitor whose active metabolite, suraxavir (GP1707D07), is primarily metabolized by cytochrome P450 3A4 (CYP3A4), raising concerns about drug-drug interactions (DDI) with CYP3A4 inhibitors. Traditional DDI ass...

Full description

Bibliographic Details

Published in:	Pharmaceutical Science Advances
Main Authors:	Lan Yang, Fan Yang, Chao-Zhuang Shen, Yan-Xin Wang, Xiao-Lin Wang, Lang lv, Yue-E Wu, Pan-Pan Ye, Bo-Hao Tang, Guo-Xiang Hao, Shou-Sheng Yan, Wei Zhao, Yi Zheng
Format:	Article
Language:	English
Published:	Elsevier 2025-12-01
Subjects:	Physiologically based pharmacokinetic modeling Drug-drug interaction Suraxavir marboxil CYP3A4 inhibitors Pharmacokinetics
Online Access:	http://www.sciencedirect.com/science/article/pii/S2773216925000339